Michael Cloonan's Stock Transactions in Sionna Therapeutics

Michael Cloonan, a director and officer of Sionna Therapeutics, Inc., has filed a Form 144 notice regarding the sale of securities. The filing details the exercise of stock options for 25,000 common shares on October 15, 2025, with an aggregate market value of $748,500. Additionally, the filing reports significant sales of common shares over the past three months, totaling $1,921,953.54 from transactions on various dates including September 29, September 26, August 27, August 26, and August 20, 2025. These transactions were executed under a 10b5-1 trading plan, indicating pre-planned sales. The filing highlights Cloonan's active management of his equity holdings in the company.